Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue

Core Insights - Adaptive Biotechnologies Corporation has concluded its strategic review, deciding to operate its Minimal Residual Disease (MRD) and Immune Medicine businesses independently while maintaining a strong capital position to support both segments [2][4] Business Update - The company reported preliminary revenue for Q1 2024, estimating total revenue between $41 million and$43 million, reflecting a 12% increase compared to Q1 2023 [3] - MRD revenue is projected to be between $31 million and$32 million for Q1 2024, marking a significant 47% increase from the same period last year [3] CFO Transition - Tycho Peterson, the current CFO, will be leaving the company, and Kyle Piskel, who has been with Adaptive for 8 years, will take over as the new CFO [4][5] - Kyle Piskel has previously served as the Interim CFO and brings over 15 years of financial expertise to the role [4]